Literature DB >> 24044761

History, background, concepts and current use of comedication and polypharmacy in psychiatry.

H-J Möller1, F Seemüller1, R Schennach-Wolff1, S Stübner2, E Rüther1, R Grohmann1.   

Abstract

Based on a careful literature search a review is presented of the history, background, concepts and current use of comedication and polypharmacy in psychiatry. The pros and cons of comedication and polypharmacy are presented, as well as their apparent increase in recent times. Possible reasons for the increase of comedication/polypharmacy are described. Both the potential advantages as well as the potential risks are discussed. The one sided view that all comedication/polypharmacy is nothing but problematic is questioned. Comedication/polypharmacy seems to be, among others, the current answer to the well-known limited efficacy and effectiveness of current monotherapy treatment strategies.

Mesh:

Year:  2013        PMID: 24044761     DOI: 10.1017/S1461145713000837

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  15 in total

1.  EPA guidance on improving the image of psychiatry.

Authors:  A M Möller-Leimkühler; H-J Möller; W Maier; W Gaebel; P Falkai
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-02-13       Impact factor: 5.270

2.  Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders.

Authors:  Taeho Greg Rhee; Robert A Rosenheck
Journal:  J Affect Disord       Date:  2019-04-08       Impact factor: 4.839

Review 3.  miRNAs as potential diagnostic biomarkers and pharmacogenomic indicators in psychiatric disorders.

Authors:  Evangelia Eirini Tsermpini; Christina I Kalogirou; George C Kyriakopoulos; George P Patrinos; Constantinos Stathopoulos
Journal:  Pharmacogenomics J       Date:  2022-06-20       Impact factor: 3.245

4.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

5.  Detailing the effects of polypharmacy in psychiatry: longitudinal study of 320 patients hospitalized for depression or schizophrenia.

Authors:  H H Stassen; S Bachmann; R Bridler; K Cattapan; D Herzig; A Schneeberger; E Seifritz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-11-25       Impact factor: 5.760

6.  Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.

Authors:  Marie Spies; Gregory M James; Neydher Berroterán-Infante; Harald Ibeschitz; Georg S Kranz; Jakob Unterholzner; Mathis Godbersen; Gregor Gryglewski; Marius Hienert; Johannes Jungwirth; Verena Pichler; Birgit Reiter; Leo Silberbauer; Dietmar Winkler; Markus Mitterhauser; Thomas Stimpfl; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

7.  Clinical correlates of augmentation/combination treatment strategies in major depressive disorder.

Authors:  M Dold; L Bartova; J Mendlewicz; D Souery; A Serretti; S Porcelli; J Zohar; S Montgomery; S Kasper
Journal:  Acta Psychiatr Scand       Date:  2018-02-28       Impact factor: 6.392

8.  Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior: A Prospective, Multicenter Study in Italy.

Authors:  E di Giacomo; A Stefana; V Candini; G Bianconi; L Canal; M Clerici; G Conte; M T Ferla; L Iozzino; G Sbravati; G Tura; R Micciolo; G de Girolamo
Journal:  Int J Neuropsychopharmacol       Date:  2020-05-27       Impact factor: 5.176

Review 9.  Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?

Authors:  Guido K W Frank
Journal:  Expert Opin Pharmacother       Date:  2020-04-13       Impact factor: 3.889

10.  Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study.

Authors:  Nobutaka Ayani; Takeshi Morimoto; Mio Sakuma; Toshiaki Kikuchi; Koichiro Watanabe; Jin Narumoto
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.